Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?

Jay Cohn, John G.F. Cleland, Jacobus Lubsen, Jeffrey S. Borer, Philippe Gabriel Steg, Michael Perelman, Faiez Zannad

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?'. Together they form a unique fingerprint.

Medicine & Life Sciences